Floatz logo

Eloxatin

Peripheral T-cell Lymphomas (PTCL)

Ruijin HospitalPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Peripheral T-cell Lymphomas (PTCL) cohort.

Asset / SponsorPhaseRating
Ro-Choep-21
Fondazione Italiana Linfomi - ETS
Phase 1/2CCC
ct125a cells
Huazhong University of Science and Technology
Early Phase 1C
Fludarabine
Huazhong University of Science and Technology
Early Phase 1C

Same molecule, other indications

Eloxatin is also rated in:

exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
colon adenocarcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
colorectal neoplasmDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →